Autonomix Medical, Inc. Share Price

Equities

AMIX

US05330T1060

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 21:30:00 08/05/2024 BST 5-day change 1st Jan Change
3.06 USD +8.90% Intraday chart for Autonomix Medical, Inc. -8.66% 0.00%
Sales 2022 - Sales 2023 - Capitalization 57.56M 4.62B
Net income 2022 -13M -1.04B Net income 2023 -1M -80.26M EV / Sales 2022 * -
Net cash position 2022 * - 0 Net cash position 2023 * - 0 EV / Sales 2023 * -
P/E ratio 2022 *
-
P/E ratio 2023 *
-
Employees 3
Yield 2022 *
-
Yield 2023 *
-
Free-Float 53.8%
More Fundamentals * Assessed data
Dynamic Chart
Autonomix Enters into Agreement with Noisefigure Research, Inc. to Develop Next Generation of Its Proprietary Microchip CI
Autonomix Medical Secures US Patent for Catheter-Based Technology to Treat Cancer-Related Pain MT
Autonomix Medical, Inc. Announces Positive Findings from Preclinical Study Demonstrating Potential to Improve Renal Denervation CI
Autonomix Appoints Jennifer Cook as Chief Business Officer CI
Autonomix Medical, Inc.(NasdaqCM:AMIX) added to S&P TMI Index CI
Autonomix Medical, Inc. Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market CI
Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market CI
Autonomix Medical, Inc. Secures Principal Investigators and Completes Clinical Training for First Human Study CI
Autonomix Medical, Inc. Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market CI
Autonomix Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday as Earnings Overshadow Potential Bond Surge Concerns MT
Top Premarket Gainers MT
Autonomix Gets Approval to Start Clinical Trial for Pancreatic Cancer Pain Treatment in Uzbekistan MT
Autonomix Re-Acquires Sensing Technology from Impulse Medical for $8 Million in Stock MT
Autonomix Medical, Inc.(NasdaqCM:AMIX) added to NASDAQ Composite Index CI
More news
1 day+8.90%
1 week-8.66%
Current month-5.26%
1 month+12.29%
3 months-41.71%
More quotes
1 week
2.71
Extreme 2.71
3.50
1 month
2.50
Extreme 2.5
3.79
Current year
2.50
Extreme 2.5
7.60
1 year
2.50
Extreme 2.5
7.60
3 years
2.50
Extreme 2.5
7.60
5 years
2.50
Extreme 2.5
7.60
10 years
2.50
Extreme 2.5
7.60
More quotes
Autonomix Medical, Inc. is a medical device company, which is focused on advancing technologies to treat diseases involving the peripheral nervous system. Its technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate peripheral neural signals with up to 1,000 times sensitivity. It is developing a two-fold technology that can both detect malfunctioning neural signals and ablate nerves in one simple procedure for pain management. It is developing its technology for pancreatic cancer and pancreatitis, conditions that can cause debilitating pain and need an effective solution. Its technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation, and chronic pain management across a disease spectrum. Its Autonomix catheter is equipped with a microchip that converts analog signals from the body to a digital signal that can be sent directly to a computer screen.
More about the company